Q-omics provides the consensus-scored RN7SL395P profile across patient tissues and cancer cell-line models. RN7SL395P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RN7SL395P is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RN7SL395P RNA expression shows 12,930 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, COAD, and THYM as cancer lineages where RN7SL395P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL395P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL395P survival associations across molecular data types. RN7SL395P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL395P RNA expression–survival associations across cancer types. High RN7SL395P expression shows unfavorable associations in KIRP, UVM, THCA and LUAD, but favorable associations in STAD and THYM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RN7SL395P RNA expression.
This table summarizes RN7SL395P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL395P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL395P shows higher tumor expression in COAD, HNSC, UCEC and LUAD. The COAD box plot shows higher RN7SL395P RNA expression in tumor versus normal tissue (log2 FC = +0.200, t-test p = .002).
This table shows molecular features associated with RN7SL395P in patient tissues and cancer cell lines. In patient samples, RN7SL395P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
